Incidence and associated factors of cetuximab-induced hypersensitivity infusion reactions in 1392 cancer patients treated in four French areas: a possible association with Lyme disease?
M Dupont,
Claire Carlier,
C Gower-Rousseau,
P Barbier-Lider,
D Botsen,
M Brasseur,
A Burgevin,
C Chourbagi,
R D’Almeida,
V Hautefeuille,
M Hentzien,
A Lambert,
M Lamuraglia,
S Lavau-Denes,
A Lopez,
D Parent,
F Slimano,
M Brugel,
O Bouché
Affiliations
M Dupont
Department of Medical Oncology, Godinot Cancer Institute
Claire Carlier
Department of Medical Oncology, Godinot Cancer Institute
C Gower-Rousseau
Department of Research and Public Health, CHU Reims
P Barbier-Lider
Department of Pharmacy, Nancy University Hospital
D Botsen
Department of Medical Oncology, Godinot Cancer Institute
M Brasseur
Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne
A Burgevin
Department of Gastroenterology and Digestive Oncology, Nancy University Hospital, Lorraine University
C Chourbagi
Department of Pharmacy, Amiens University Hospital
R D’Almeida
Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne
V Hautefeuille
Department of Gastroenterology and Digestive Oncology, Amiens University Hospital, University of Picardie Jules Verne
M Hentzien
Department of Infectious Diseases and Internal Medicine, CHU Reims, University of Reims Champagne-Ardenne
A Lambert
Department of Medical Oncology, Lorraine Cancer Institute
M Lamuraglia
Department of Medical Oncology, Amiens University Hospital, University of Picardie Jules-Vernes
S Lavau-Denes
Department of Medical Oncology, Limoges University Hospital
A Lopez
Department of Gastroenterology and Digestive Oncology, Nancy University Hospital, Lorraine University
D Parent
Department of Pharmacy, Godinot Cancer Institute
F Slimano
Department of Pharmacy, CHU Reims, University of Reims Champagne-Ardenne
M Brugel
Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne
O Bouché
Department of Gastroenterology and Digestive Oncology, CHU Reims, University of Reims Champagne-Ardenne
Highlights In a large series of 1392 patients, the 266 patients treated in the French area with the highest incidence of Lyme disease were at a higher risk of cetuximab-induced hypersensitivity infusion reactions compared to those from other areas (16.4% versus 6.7%, 7.1% and 7.0% in medium-, low- and very-low-risk areas; P = 0.0015). The risk of cetuximab-induced hypersensitivity infusion reactions in head and neck squamous cell carcinoma patients was higher only in the area with the highest incidence of Lyme disease. Age, sex, premedication, primary cancer location and chemotherapy regimen type had no impact on the incidence of cetuximab-induced infusion reactions in the overall population.
